Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$19.98

0.54 (2.78%)

15:24
01/15/20
01/15
15:24
01/15/20
15:24

Alkermes still gets little credit beyond base business, says JPMorgan

JPMorgan analyst Cory Kasimov noted that Alkermes Chairman and CEO Richard Pops reviewed the company's current commercial products and discussed the '3831 opportunity and the company's pipeline at the JP Morgan Healthcare Conference. Talking about the '3831 NDA submission that was announced in the fourth quarter, Pops said the company expects the application to be accepted "very soon" and stressed that doctors are excited about the efficacy profile for '3831 without the effect of weight gain, according to Kasimov. The analyst, who continues to believe the company's share price gives it little credit beyond the base business, reiterated his Overweight rating on Alkermes coming out of the event.

  • 15

    Jan

ALKS Alkermes
$19.98

0.54 (2.78%)

11/01/19
HCWC
11/01/19
NO CHANGE
Target $26
HCWC
Neutral
Alkermes price target lowered to $26 from $28 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered his price target for Alkermes (ALKS) to $26 from $28 and reiterates a Neutral rating on the shares. With announced rationalization of the cost structure and launch of Vumerity as well as expected launch of ALKS-3831, the analyst expects the company to achieve non-GAAP profitability. He thinks Vumerity could eventually represent 25%-30% of the Tecfidera/Vumerity franchise, although he would like to see how aggressively Biogen (BIIB) promotes Vumerity before ascribing that much value. However, Tsao is doubtful that earnings based on the launches of Vumerity and ALKS-3831 can command an earnings multiple "that can take shares meaningfully" higher. Sentiment around ALKS-4230 could be the key driver of Alkermes shares over the next two years, the analyst adds.
11/11/19
MSCO
11/11/19
NO CHANGE
Target $20
MSCO
Equal Weight
Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley
Morgan Stanley analyst David Risinger noted that Alkermes presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer annual meeting. While he noted "encouraging signals" such as a patient with pancreatic cancer with stable disease on monotherapy for six months as well as two partial responses from patients on combination therapy, there were also "disappointing signals" such as the fact that no patients had partial response or complete response in the monotherapy dose escalation stage, Risinger said. Overall, he thinks that data presented at SITC were "too preliminary to assess" the potential of 4230 and he looks forward to future updates, said Risinger, who keeps an Equal Weight rating on Alkermes shares with a $20 price target.
11/18/19
STFL
11/18/19
NO CHANGE
Target $23
STFL
Hold
Alkermes made 'nice strategic move' in buying Rodin, says Stifel
Stifel analyst Paul Matteis views Alkermes' acquisition of Rodin as a "nice strategic move," saying it offers an entry into an interesting emerging area of neuroscience at a reasonable price. Rodin's portfolio could be applied to a wide array of central nervous system indications where synaptic loss or dysfunction is core to the pathology, including Alzheimer's, Huntington's or even psychiatric ailments like depression and schizophrenia, Matteis tells investors in a research note. However, this is an early stage deal, and unlikely to be immediately stock moving, the analyst adds. Matteis keeps a Hold rating on Alkermes with a $23 price target.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $22
PIPR
Neutral
Alkermes deal strengthens early-stage pipeline, says Piper Jaffray
Alkermes strengthened its early-stage pipeline with the acquisition of Rodin Therapeutics and its oral, selective histone deactelyase inhibitors platform, Piper Jaffray analyst Danielle Brill tells investors in a research note. Building out its research and development efforts in the neurodegenerative space will allow Alkermes to leverage its existing expertise, adds the analyst, who views the company's effort to expand its pipeline positively. However, Brill notes that the acquired assets are still in very early development "and won't be value-creating for some time." To get more constructive on the shares, the analyst wants to see Alkermes add clinical stage assets "that are more de-risked" to its pipeline. Brill keeps a Neutral rating on the shares with a $22 price target.

TODAY'S FREE FLY STORIES

CLGX

CoreLogic

$44.99

-0.365 (-0.80%)

17:20
01/22/20
01/22
17:20
01/22/20
17:20
Earnings
Breaking Earnings news story on CoreLogic »

CoreLogic sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 09

    Mar

TWNK

Hostess Brands

$13.83

-0.06 (-0.43%)

17:19
01/22/20
01/22
17:19
01/22/20
17:19
Initiation
Hostess Brands initiated  »

Hostess Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

PAYC

Paycom

$303.73

3.96 (1.32%)

, WCG

WellCare

$345.79

5.27 (1.55%)

17:18
01/22/20
01/22
17:18
01/22/20
17:18
Hot Stocks
Paycom to replace WellCare in S&P 500 at open on 1/28 »

Centene (CNC) is…

PAYC

Paycom

$303.73

3.96 (1.32%)

WCG

WellCare

$345.79

5.27 (1.55%)

CNC

Centene

$66.72

1.24 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

  • 13

    Feb

AMRN

Amarin

$20.82

-0.24 (-1.14%)

17:18
01/22/20
01/22
17:18
01/22/20
17:18
Hot Stocks
Amarin says payers response on new Vascepa indication 'very positive' »

In a statement to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$35.35

-0.32 (-0.90%)

17:17
01/22/20
01/22
17:17
01/22/20
17:17
Hot Stocks
Washington Federal increases quarterly cash dividend 5% to 22c per share »

The board of Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Feb

FBNC

First Bancorp

$37.42

-0.37 (-0.98%)

17:16
01/22/20
01/22
17:16
01/22/20
17:16
Earnings
First Bancorp reports Q4 EPS 71c, consensus 78c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$46.83

-0.085 (-0.18%)

17:12
01/22/20
01/22
17:12
01/22/20
17:12
Initiation
TreeHouse initiated  »

TreeHouse assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 17

    Feb

LW

Lamb Weston

$91.19

0.01 (0.01%)

17:11
01/22/20
01/22
17:11
01/22/20
17:11
Initiation
Lamb Weston initiated  »

Lamb Weston assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

RP

RealPage

$57.51

-0.29 (-0.50%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Hot Stocks
RealPage to acquire Modern Message, terms not disclosed »

RealPage has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

TER

Teradyne

$73.57

2.04 (2.85%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Hot Stocks
Teradyne up 8% after Q4 earnings beat and above-consensus Q1 outlook »

Shares of Teradyne are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HAIN

Hain Celestial

$25.48

(0.00%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Initiation
Hain Celestial initiated  »

Hain Celestial assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$73.57

2.04 (2.85%)

17:07
01/22/20
01/22
17:07
01/22/20
17:07
Hot Stocks
Teradyne CEO says Q1 outlook reflects the impact of customer production ramps »

CEO Mark Jagiela states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

OSBC

Old Second Bancorp

$13.21

0.14 (1.07%)

17:07
01/22/20
01/22
17:07
01/22/20
17:07
Earnings
Breaking Earnings news story on Old Second Bancorp »

Old Second Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CCNE

CNB Financial

$31.13

-0.2 (-0.64%)

17:06
01/22/20
01/22
17:06
01/22/20
17:06
Earnings
CNB Financial reports Q4 EPS 69c, consensus 69c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$73.57

2.04 (2.85%)

17:06
01/22/20
01/22
17:06
01/22/20
17:06
Hot Stocks
Teradyne raises quarterly dividend to 10c from 9c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:05
01/22/20
01/22
17:05
01/22/20
17:05
Hot Stocks
Teradyne board authorizes stock buyback of $1B »

Teradyne board authorized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:04
01/22/20
01/22
17:04
01/22/20
17:04
Earnings
Teradyne sees Q1 EPS 86c-96c, consensus 62c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:03
01/22/20
01/22
17:03
01/22/20
17:03
Earnings
Teradyne reports Q4 adjusted EPS 88c, consensus 79c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

OII

Oceaneering

$14.33

-0.08 (-0.56%)

17:02
01/22/20
01/22
17:02
01/22/20
17:02
Hot Stocks
Oceaneering names Earl Childress to succeed Barrett asd SVP business development »

Oceaneering International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 23

    Mar

LYTS

LSI Industries

$6.47

0.13 (2.05%)

17:01
01/22/20
01/22
17:01
01/22/20
17:01
Hot Stocks
LSI Industries to sell Ohio manufacturing facility for $8M »

LSI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Mar

PYPL

PayPal

$115.52

-0.62 (-0.53%)

17:01
01/22/20
01/22
17:01
01/22/20
17:01
Hot Stocks
UnionPay, PayPal enter global partnership agreement »

UnionPay International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 09

    Mar

JAGX

Jaguar Health

$0.82

-0.1295 (-13.60%)

16:57
01/22/20
01/22
16:57
01/22/20
16:57
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$22.51

0.36 (1.63%)

16:56
01/22/20
01/22
16:56
01/22/20
16:56
Earnings
Customers Bancorp reports Q4 core EPS 76c, consensus 74c »

Reports Q4 NII $77.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AFH

Atlas Financial

$0.59

-0.0392 (-6.22%)

16:55
01/22/20
01/22
16:55
01/22/20
16:55
Hot Stocks
Atlas Financial announces LOI for sale of Gateway Insurance to Buckle »

Atlas Financial Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$65.75

0.79 (1.22%)

16:50
01/22/20
01/22
16:50
01/22/20
16:50
Hot Stocks
Lennar CFO Diane Bessette sells almost $370K in company shares »

Lennar CFO Diane Besette…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.